A patient treated with a single dose of AdAlta’s experimental CAR T cell therapy EW 001 has remained free of cancer recurrence for two years, marking a significant milestone in the company’s ongoing mesothelioma study in China.

Amplia Therapeutics has entered into a clinical trial collaboration and supply agreement with Eli Lilly to evaluate whether its investigational FAK inhibitor narmafotinib can improve treatment outcomes when combined with Lilly’s next-generation KRAS G12C inhibitor olomorasib.

Neurizon Therapeutics has entered into a strategic research and development financing facility with the Dare Capital Loan Fund, providing up to $17.5 million in additional capital to support its work on treatments for neurodegenerative diseases.

Noxopharm has reported preclinical results showing that its technology can help the immune system recognise cellular RNA that would normally fail to trigger an anti-cancer response.

Entropy Neurodynamics has received approval from the Human Research Ethics Committee to begin a Phase 1b/2a basket study of TRP-8803, its proprietary intravenous psilocin formulation.

Over six years, AUScelerate’s first Targeted Translation Research Accelerator program quietly reshaped the landscape for heart and diabetes care in Australia, unlocking $220 million in investment and propelling dozens of new treatments, technologies and support services closer to patients.

Professor Trent Munro, General Manager of the BRIJ, and Rebekah Cassidy, CEO of AusBiotech, spoke with BiotechDispatch about the precinct’s contribution to how Australia’s life sciences sector is moving from scientific promise to commercial impact.

Imugene has reported another encouraging result from the concurrent BTKi cohort of its azer-cel Phase 1b trial, announcing a third response in patients treated with the off‑the‑shelf allogeneic CAR T therapy.

Radiopharm Theranostics has secured backing from institutional investors for a capital-raising effort that will support the clinical-stage company's development.

OncoSil Medical has reported encouraging results from an independent formulation study showing that its phosphorus-32 microparticles can be suspended and delivered at substantially higher concentrations than those currently used in commercial practice, without increasing the flow resistance clinicians experience during procedures.

Tenmile's Dr Steve Burnell says it is often overlooked that success in biotech rests not on the science alone, but on a company's capital structure and on whether its investors understand the full development pathway.

CLINUVEL Pharmaceuticals has announced a strategic reorganisation that will see its corporate headquarters relocate to the United States and its global workforce realigned as the company positions itself for a US listing.

Radiopharm Theranostics has announced encouraging results from its Phase 2b trial of RAD101, a Fluorine-18 labelled PET tracer that targets fatty acid synthase to detect suspected recurrent brain metastases.

Proteomics International Laboratories has announced a national distribution agreement with Healius that will make the Promarker portfolio available across Australia through the Healius pathology network.

BLS Pharmaceuticals has entered a non-binding heads of agreement with Trexapharm to explore the Australian commercialisation of TREXAVIVE, a proprietary, patented neurotherapy being developed for treatment-resistant depression.

Telix Pharmaceuticals has reported robust commercial momentum in the quarter ended June 30, 2026, with group revenue of US$247 million, up 21 per cent year over year and 7 per cent from the prior quarter.

LTR Pharma has taken a major step toward its planned US commercial launch by executing a definitive agreement with Strive Specialties, converting a previously announced binding term sheet into a long-form commercial arrangement for the nationwide supply of its therapy in the United States.